Ischemic cardiomyopathy
Conditions
Interventions
Experimental group (Part 1: The Effects of Transcutaneous Electrical Acupoint Stimulation of the Neiguan Acupoint on Coronary Sinus Blood Flow Parameters):The physician conducting the trial located th
Control group (Part 1: The Effects of Transcutaneous Electrical Acupoint Stimulation of the Neiguan Acupoint on Coronary Sinus Blood Flow Parameters):The patient is connected to the electroacupuncture
Group A (Part 2:Dose-response relationship of transcutaneous electrical acupoint stimulation at the Neiguan acupoint on coronary sinus blood flow parameters):Apply an electroacupuncture patch to the N
Group B (Part 2: Dose-response relationship of transcutaneous electrical acupoint stimulation at the Neiguan acupoint on coronary sinus blood flow parameters):Apply an electroacupuncture patch to the
Group C (Part 2: Dose-response relationship
Sponsors
Chengdu No.1 Orthopedics Hospital
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > 70 years; ASA physical status grades I–V; gender; 2. 18= 28); 4. Full understanding of this trial, willingness to participate in this clinical trial, and signing of the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled hypertension and diabetes (systolic blood pressure >=160 mmHg and/or diastolic blood pressure >=100 mmHg, blood glucose >=15.0 mmol/L); 2. Patients with multiple-site fractures and those with concurrent injuries to thoracic or abdominal organs; 3. Patients with a history of psychiatric disorders, abuse of psychotropic medications or anesthetic drugs, who are unable to cooperate with transcutaneous electrical acupoint stimulation therapy and bedside echocardiography; 4. Severe hepatic or renal disease, confirmed pulmonary hypertension, heart failure (New York Heart Association Class > I), or shunt-type cardiac diseases; 5. Presence of inflammation, ulcers, scars, or skin breakdown around the target acupoints; 6. Patients with previously implanted devices such as defibrillators, cardiac pacemakers, or coronary stents.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Inferior vena cava respiratory variation;Cardiac output;Hemodynamic parameters (heart rate, mean arterial pressure, oxygen saturation);Myocardial oxygen consumption;Coronary sinus blood flow parameters;Inferior vena cava respiratory variation;Cardiac output;Vital signs;Intraoperative medication use;Postoperative pain score;Incidence of cardiovascular adverse events within 1 month postoperatively; | — |
Primary
| Measure | Time frame |
|---|---|
| Coronary sinus blood flow parameters; | — |
Countries
China
Contacts
Public ContactWu Wenzhi
Chengdu No.1 Orthopedics Hospital
Outcome results
None listed